Pipeline

Le ​Life Sciences​ stanno migliorando radicalmente le possibilità di cura, anche per malattie ​fino a poco tempo fa ​prive di una risposta terapeutica. Le nuove conoscenze combinate con la potenza di calcolo sempre crescente e il progresso dell'intelligenza artificiale potranno​ presto​ dare risposta ai bisogni ​insoddisfatti ​de​i pazienti ​ancor più ​rapidamente​.

Pipeline di ricerca

Con la nostra pipeline di ricerca e sviluppo, ci rivolgiamo ad alcune delle aree terapeutiche a più alto bisogno di cura.

Eye

  • Cenegermin - bkbj
    Cheratite Neurotrofica (NK)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Cenegermin - bkbj
    Difetto Persistente dell’Epitelio Corneale (PCED)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Cenegermin - bkbj
    Neuropatia Ottica Ischemica Anteriore Non Arteritica (NAION)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • DFL 24498
    Cheratocongiuntivite Atopica (AKC)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Undisclosed molecule
    La Graft-versus-Host Disease oculare, o malattia oculare del trapianto contro l’ospite (oGvHD)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed

Brain

  • Undisclosed molecule
    Encefalopatia Ipossico-Ischemica Neonatale (NHIE)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Undisclosed molecule
    Paralisi Cerebrale Infantile (CP)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • Undisclosed molecule
    Trauma Cranico (TBI)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed

Pain

  • DF2755A
    Dolore Cronico
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed
  • DFL 23693
    Osteoartrite (OA)
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    Marketed

Pubblicazioni

Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings

Autori: Simone L Mattioli, Prashant Dogra, Francesco Longobardi, Grazia Casiello, Lucia Apparente, Nicola Detta, Rubina Novelli, Andrea Aramini, Franca Cattani, Maria I Antonangeli, Tiziana Romeo, Marcello Allegretti, Zhihui Wang, Cleide G Machado, Renata Pasqual

Clinical-grade intranasal NGF fuels neurological and metabolic functions of Mecp2-deficient mice

Autori: Diego Pozzer, Marzia Indrigo, Martina Breccia, Elena Florio, Camilla Aurora Franchino, Giuseppina De Rocco, Francesca Maltecca, Antonio Fadda, Marzia Rossato, Andrea Aramini, Marcello Allegretti, Angelisa Frasca, Lidia De Filippis, Nicoletta Landsberger

Cenegermin for the Treatment of Moderate or Severe Neurotrophic Keratopathy: Results from a Prospective, Phase IV, Open-Label Study in China

Autori: Suxia Li, Jianjiang Xu, Jin Yuan, Zhiqiang Pan, Giacomo Siri, Scott G. Hauswirth, Flavio Mantelli & Weiyun Shi

The dual non-competitive CXCR1/2 inhibitor ladarixin impairs neutrophil extravasation without altering intravascular adhesion

Autori: Matteo Napoli, Sebastian Sitaru, Agnes Budke, Anna Kammerl, Georgia Querner, Roland Immler, Ina Rohwedder, Sonja Seifert, Bartolo Ferraro, Ludwig Weckbach, Sergio Catz, Andrea Aramini, Pier Giorgio Amendola, Marcello Allegretti, Riccardo Bertini, Monika P

Evaluation of the gastrotolerability of ketoprofen, lysine, and gabapentin co-crystal administration in an in vitro model of gastric epithelium: a proteomic update

Autori: Francesco D'Egidio, Laura Brandolini, Vanessa Castelli, Massimiliano Quintiliani, Andrea Aramini, Annamaria Cimini, Marcello Allegretti, Michele d'Angelo

Scopri la scienza alla base della nostra missione

Esplora il portfolio di ricerca Dompé

Grazie alla nostra rete globale di ricerca e sviluppo e a un approccio basato sull’open innovation, continuiamo a esplorare il potenziale trasformativo di NGF e altre molecole, trasformando le scoperte scientifiche in terapie capaci di rispondere ai bisogni clinici più urgenti dei pazienti.

Marcello Allegretti, Chief Scientific Officer

La nostra pipeline si fonda sul rigore scientifico e si ispira al potenziale trasformativo di NGF e di altre ricerche innovative per ridefinire il modo in cui trattiamo le patologie oftalmologiche, neurologiche e di trattamento del dolore.

Ahmed Enayetallah, Chief Development Officer

Riferimenti bibliografici

  1. Jeonghyun (Esther) Kwon et al., “Emerging Treatments for Persistent Corneal Epithelial Defects,” Vision 9, no. 2 (April 1, 2025): 26, https://doi.org/10.3390/vision9020026.
  2. Jeonghyun (Esther) Kwon et al., “Emerging Treatments for Persistent Corneal Epithelial Defects,” Vision 9, no. 2 (April 1, 2025): 26, https://doi.org/10.3390/vision9020026.
  3. Valérie Biousse and Nancy J Newman, “Diagnosis and Clinical Features of Common Optic Neuropathies,” The Lancet Neurology 15, no. 13 (December 2016): 1355–67, https://doi.org/10.1016/s1474-4422(16)30237-x.
  4. Joseph J. Chen et al., “Atopic Keratoconjunctivitis: A Review,” Journal of the American Academy of Dermatology 70, no. 3 (December 2013): 569–75, https://doi.org/10.1016/j.jaad.2013.10.036.
  5. Brett Bielory and Leonard Bielory, “Atopic Dermatitis and Keratoconjunctivitis,” Immunology and Allergy Clinics of North America 30, no. 3 (August 2010): 323–36, https://doi.org/10.1016/j.iac.2010.06.004.
  6. “Atopic Keratoconjunctivitis,” National Organization for Rare Disorders, May 1, 2025, https://rarediseases.org/mondo-disease/atopic-keratoconjunctivitis/.
  7. Brett Bielory and Leonard Bielory, “Atopic Dermatitis and Keratoconjunctivitis.”
  8. Atopic keratoconjunctivitis - eyewiki, accessed October 7, 2025, https://eyewiki.org/Atopic_Keratoconjunctivitis.
  9. Hasanain Shikari, Joseph H. Antin, and Reza Dana, “Ocular Graft-versus-Host Disease: A Review,” Survey of Ophthalmology 58, no. 3 (May 2013): 233–51, https://www.surveyophthalmol.com/article/S0039-6257(12)00184-1/abstract.
  10. Espana EM, et al. Corneal complications of chronic graft-versus-host disease: prevention and treatment. Cornea. 2010;29(2):119-127.
  11. “Neonatal Hypoxic-Ischemic Encephalopathy,” Nationwide Children’s Hospital, n.d., https://www.nationwidechildrens.org/conditions/health-library/neonatal-hypoxic-ischemic-encephalopathy.
  12. Katie Lavender, ed., “Cerebral Palsy Statistics: Facts and Insights on CP,” Cerebral Palsy Guide, June 17, 2025, https://www.cerebralpalsyguide.com/cerebral-palsy/statistics/#:~:text=Since%20cerebral%20palsy%20affects%20about,is%200.29%25%20of%20the%20population.
  13. Jill Daugherty et al., “Traumatic Brain Injury–Related Deaths by Race/Ethnicity, Sex, Intent, and Mechanism of Injury — United States, 2000–2017,” MMWR. Morbidity and Mortality Weekly Report 68, no. 46 (November 22, 2019): 1050–56, https://doi.org/10.15585/mmwr.mm6846a2.
  14. Rolf-Detlef Treede et al., “Chronic Pain as a Symptom or a Disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11),” Pain 160, no. 1 (January 2019): 19–27, https://doi.org/10.1097/j.pain.0000000000001384.
  15. Rikard SM, Strahan AE, Schmit KM, Guy GP Jr., “Chronic Pain Among Adults — United States, 2019–2021,” MMWR Morb Mortal Wkly Rep 2023;72:379–385. DOI: http://dx.doi.org/10.15585/mmwr.mm7215a1.
  16. Liping Tong et al., “Current Understanding of Osteoarthritis Pathogenesis and Relevant New Approaches,” Bone Research 10, no. 1 (September 20, 2022), https://doi.org/10.1038/s41413-022-00226-9.
  17. “OA Prevalence and Burden,” Osteoarthritis Action Alliance, https://oaaction.unc.edu/oa-module/oa-prevalence-and-burden/.